AstraZeneca's GLP-1 Pill Heads To Late-Stage Trials

AstraZeneca Plc (NASDAQ: AZN ) is advancing its oral GLP-1 receptor agonist, elecoglipron, into an extensive Phase 3 development program after the drug delivered significant weight-loss and diabetes-control results in two Phase 2b studies. The findings , presented at the 2026 Scientific Sessions of the American Diabetes Association and published in The Lancet , support the company's efforts to expand its cardiometabolic, renal, and weight-management portfolio. Elecoglipron is an investigational oral, once-daily, small-molecule GLP-1 receptor agonist that mimics the natural GLP-1 hormone.  VISTA Trial Demonstrates Significant Weight Reduction The VISTA study enrolled 310 adults with obesity or overweight and at least one related comorbidity . Participants receiving elecoglipron 75 mg achieved an average body-weight reduction of 10.5% at 26 weeks, compared with 0.6% for placebo. Weight loss continued through week 36, reaching 11.8% in the treatment group versus 0.3% with placebo. The trial also met its co-primary endpoint measuring the proportion of participants achieving ... Full story available on Benzinga.com